12月11日 - ** 药物开发商Sarepta TherapeuticsSRPT.O宣布债务再融资计划后，股价盘前下跌8.2%至20.38美元。
** SRPT 同意部分持有人将 2027 年到期的 2.914 亿美元 1.25% 可交换票据转换为 2030 年到期的等额 4.875% 可交换票据
** 新票据将与 8 月份发行的 6.02 亿美元票据构成同一系列，使 2030 年到期的 4.875% 流通票据总额达到 8.934 亿美元。
** 29 家券商中有 9 家将该股评级为 "买入 "或更高，15 家为 "持有"，5 家为 "卖出 "或更低；他们的 PT 中值为 18 美元 - LSEG 数据
** 截至上次收盘，该股今年累计下跌 81.7
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.